MedTrace Logo

Dose Response Study of Patients With Erythematous Rosacea

NCT01186068 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 175

Last updated 2010-11-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the dose-response relationship (effect) of four concentrations of V-101 Cream in patients with erythematous(redness) rosacea.

Conditions

  • Erythematous (Type One) Rosacea

Interventions

DRUG

V-101

Cream QD

OTHER

vehicle

Cream QD

Sponsors & Collaborators

  • Accenture

    collaborator INDUSTRY

  • Vicept Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Stacy R Smith, MD · Therapeutics Clinical Research

  • Michael T Jarratt, MD · Derm Research, PLLC

  • Leslie S Baumann, MD · Baumann Cosmetic & Research Institute

  • Joseph F Fowler, MD · Dermatology Specialists Research

  • Robert T Matheson, MD · Oregon Medical Research Center, PC

  • Daniel M Stewart, DO · DBA Michigan Center for Skin Care Research

  • Eduardo Tschen, MD · Academic Dermatology Associates

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01186068 on ClinicalTrials.gov